Neratinib protects pancreatic beta cells in diabetes
Type 1 as well as type 2 diabetes are characterized by a loss of insulin-producing β-cells. Here the authors show that the FDA-approved drug neratinib has beneficial effects on β-cell survival, insulin secretion, and glycemic control in mouse models of diabetes.
Guardado en:
Autores principales: | Amin Ardestani, Sijia Li, Karthika Annamalai, Blaz Lupse, Shirin Geravandi, Aleksandra Dobrowolski, Shan Yu, Siying Zhu, Tyler D. Baguley, Murali Surakattula, Janina Oetjen, Lena Hauberg-Lotte, Raquel Herranz, Sushil Awal, Delsi Altenhofen, Van Nguyen-Tran, Sean Joseph, Peter G. Schultz, Arnab K. Chatterjee, Nikki Rogers, Matthew S. Tremblay, Weijun Shen, Kathrin Maedler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/627d0ae36e6e4ac994b3607b5e658ae4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Hippo kinase LATS2 impairs pancreatic β-cell survival in diabetes through the mTORC1-autophagy axis
por: Ting Yuan, et al.
Publicado: (2021) -
Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger K, et al.
Publicado: (2015) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
After COVID-19. Reorientation of crisis management in crisis
por: Zbyslaw Dobrowolski
Publicado: (2020) -
The supreme audit institutions readiness to uncertainty
por: Zbyslaw Dobrowolski
Publicado: (2020)